Last reviewed · How we verify

NCT01376232: DDI

Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)

Completed Phase 1 Last updated 9 June 2017
What this trial tests

Phase 1 trial testing GSK1278863 in Anaemia in 23 participants. Completed in 20 December 2010.

Timeline
8 November 2010
Primary endpoint
20 December 2010
20 December 2010

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingnone
Primary purposeother
Enrollment23
Start date8 November 2010
Primary completion20 December 2010
Estimated completion20 December 2010
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 55, any sex, with Anaemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil),\]

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Daprodustat: First Approval.
    Dhillon S. · · 2020 · cited 47× · PMID 32880805 · DOI 10.1007/s40265-020-01384-y
  2. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863.
    Johnson BM, Stier BA, Caltabiano S. · · 2014 · cited 38× · PMID 27128455 · DOI 10.1002/cpdd.83

Verify or expand the search:

Other trials of GSK1278863

Trials testing the same drug.

Other recruiting trials for Anaemia

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01376232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing